Nabriva Therapeutics plc (Nasdaq: NBRV)

https://www.nabriva.com

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics’ medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics’ lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics believes lefamulin is well-positioned for use as a first-line empiric monotherapy for the treatment of moderate to severe CABP due to its novel mechanism of action, targeted spectrum of activity, resistance profile, achievement of substantial drug concentration in lung tissue and fluid, oral and IV formulations and a favorable tolerability profile. Nabriva Therapeutics is exploring potential further development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use. Nabriva Therapeutics owns exclusive, worldwide rights to lefamulin, which is protected by composition of matter patents issued in the U.S., Europe and Japan. *

	Start	2017-05-23 restructured
	Group	Nabriva (Group)
	Predecessor	Nabriva Therapeutics AG
	Industry	anti-infective drug
	Industry 2	lefamulin (BC-3781)
	Person	Schroeder, Ted (Nabriva 201807– CEO before Zavante Therapeutics + Cadence Pharmaceuticals + Élan)

	Region	Dublin
	Country	Ireland, Republic of
	Street	25–28 North Wall Quay IFSC
	City	Dublin 1
	Tel	+353-1-649-2000
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2019-01-31)
	Currency	USD
	Annual sales	9,656,000 (revenues, total, consolidated (2018) 2018-12-31)
	Profit	-114,780,000 (2018-12-31)
	Cash	102,003,000 (2018-12-31)

		* Document for »About Section«: Nabriva Therapeutics plc. (9/20/17). "Press Release: Nabriva Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference". Dublin & King of Prussia, PA.

		Record changed: 2023-07-10